Immunovant Risk Adjusted Performance
| IMVT Stock | | | USD 16.95 1.37 7.48% |
Immunovant risk-adjusted-performance technical analysis lookup allows you to check this and other technical indicators for Immunovant or any other equities. You can select from a set of available technical indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations and data normalization technicques. Please check also
Equity Screeners to view more equity screening tools
Immunovant has current Risk Adjusted Performance of 0.0575.
RAP | = | (ER[a] - RFR) * STD[b])/STD[b]RFR |
| = | 0.0575 | |
Immunovant Risk Adjusted Performance Peers Comparison
Immunovant Risk Adjusted Performance Relative To Other Indicators
Immunovant is rated
third overall in risk adjusted performance category among its peers. It is currently under evaluation in maximum drawdown category among its peers reporting about
263.95 of Maximum Drawdown per Risk Adjusted Performance. The ratio of Maximum Drawdown to Risk Adjusted Performance for Immunovant is roughly
263.95
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.